Summary of TScan Therapeutics (TCRX) 2025 Conference Call Company Overview - TScan Therapeutics is a clinical-stage company focused on next-generation TCR T cell therapy, founded in 2018 [2][3] - The company has two main clinical programs: one for hematologic malignancies (AML, MDS, ALL) and another for solid tumors [3][4] Hematologic Malignancies Program - Promising data reported at ASH in December, showing only 8% relapse rate in treated patients compared to 33% in the control arm [4][24] - The pivotal trial for the heme program is set to launch this year, with multiple clinical catalysts expected [5][25] - The program targets patients undergoing allogeneic bone marrow transplants, aiming to improve outcomes and reduce relapse rates [9][10] - The treatment involves engineering donor T cells to target residual cancer cells post-transplant, minimizing side effects [13][15] - The study design includes a synthetic control arm using data from the CIBMTR database, aiming for a hazard ratio of 0.6 with 85% power [28][29] - The addressable patient population in the U.S. is approximately 7,350 annually, with an estimated 1,000 patients meeting the trial criteria [31][32] - Potential market opportunity estimated in the multibillion-dollar range, with pricing for TCR therapies around $727,000 [34][35] Solid Tumors Program - The solid tumors strategy focuses on addressing tumor heterogeneity through multiplex therapy, using multiple TCRs simultaneously [38][39] - The company has seven TCRs cleared by the FDA, currently in a phase one clinical trial called the Plexity study [41][42] - The first patient is expected to be treated with multiplex therapy in the first half of this year, with safety and efficacy data to be reported by year-end [46][51] - The focus will be on HPV-positive cancers (head and neck, cervical, anal) and HPV-negative cancers (non-small cell lung cancer, sarcoma) [48][50] - A significant percentage of patients in these indications qualify for multiplex therapy, indicating a substantial addressable market [50] Key Data and Findings - In the heme program, 100% donor chimerism was achieved in treated patients, significantly reducing relapse risk compared to the control group [22][24] - The treatment arm showed a much lower probability of relapse (8%) compared to the control arm [24] - The company plans to expand its therapy to other HLA types, potentially doubling the addressable patient population [36][37] Future Milestones - Launch of the pivotal study for the heme program in the second half of the year [52] - Filing of an IND for expanded HLA TCRs by year-end [52] - Continued updates on safety and efficacy data for both heme and solid tumor programs throughout the year [52]

Core Viewpoint - TScan Therapeutics, Inc. is set to present at the Jefferies Global Healthcare Conference on June 4, 2025, highlighting its focus on T cell receptor-engineered therapies for cancer treatment [1]. Company Overview - TScan Therapeutics is a clinical-stage biotechnology company dedicated to developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed for patients with hematologic malignancies, specifically to prevent relapse after allogeneic hematopoietic cell transplantation, as part of the ALLOHA Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that target diverse antigens and are compatible with multiple HLA types, to create customized multiplex TCR-T therapies for various cancers, including the PLEXI-T Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3].

Summary of T SCAN Therapeutics Conference Call Company Overview - The conference featured T SCAN Therapeutics, represented by CEO Gavin Macbeth, at BofA's 2025 health care conference [1] Core Insights and Arguments - T SCAN is developing a program called Orca 21, which aims to combine IL-23 and IL-17 therapies for psoriasis treatment. The strategy involves using IL-17 for rapid skin clearance followed by IL-23 for maintenance [3][4] - The company is currently in Phase 1 clinical trials for the Orca 1 program, with results expected in the second half of the year. A Phase 2 study will also commence in the same timeframe, with psoriasis data anticipated next year [5][6] - T SCAN has raised over $475 million last year, providing sufficient funding for ongoing clinical trials and a runway for an additional year without needing further capital [6] Key Upcoming Events - Key milestones include: - Phase 1 readout for Orca 1 in the second half of this year - Phase 2 study initiation for psoriasis in the second half of this year - Pharmacokinetic (PK) data expected in the first half of next year [5][6] Important Metrics - The company aims for a 50-day half-life for the molecule to enable six-month dosing and a 75-day half-life for annual dosing, which would be a significant advancement in treatment options [9][10] Additional Considerations - The combination therapy approach has garnered excitement from physicians, indicating potential market interest and acceptance [4] - The reproducibility of psoriasis data across trials is highlighted as a critical factor for the company's future success [5]

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.14%. A quarter ago, it was expected that this company would post a loss of $0.27 per share when it actually produced a loss of $0.29, delivering a surprise of -7.41%.Over the last four quarters, the company has ...

Company Presentation May 2025 Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Company's plans, progress, and timing relating to the Company's solid tumor programs and the presentation of data, the Company's current and future research and development plans or expectations, the str ...

[PART I. FINANCIAL INFORMATION](index=7&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (Unaudited)](index=7&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents TScan Therapeutics, Inc.'s unaudited condensed consolidated financial statements as of March 31, 2025, highlighting a net loss of $34.1 million and $251.7 million in cash and equivalents [Condensed Consolidated Balance Sheets](index=7&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets decreased to $332.7 million from $371.1 million, primarily due to reduced cash, while liabilities and equity also declined Condensed Consolidated Balance Sheets (in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $154,108 | $178,689 | | Marketable securities | $97,581 | $111,421 | | Total current assets | $254,836 | $292,722 | | Total assets | $332,709 | $371,118 | | **Liabilities and Stockholders' Equity** | | | | Total current liabilities | $29,816 | $35,956 | | Total liabilities | $122,507 | $130,148 | | Total stockholders' equity | $210,202 | $240,970 | | Total liabilities and stockholders' equity | $332,709 | $371,118 | [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Collaboration and license revenue increased to $2.2 million, but rising operating expenses led to a wider net loss of $34.1 million for the three months ended March 31, 2025 Condensed Consolidated Statements of Operations (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Collaboration and license revenue | $2,171 | $566 | | Research and development | $29,788 | $24,857 | | General and administrative | $8,633 | $7,082 | | **Total operating expenses** | **$38,421** | **$31,939** | | Loss from operations | ($36,250) | ($31,373) | | **Net loss** | **($34,127)** | **($30,142)** | | Net loss per share, basic and diluted | ($0.26) | ($0.32) | [Condensed Consolidated Statements of Cash Flows](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $37.6 million in Q1 2025, partially offset by $13.5 million from investing activities, resulting in a net cash decrease Condensed Consolidated Statements of Cash Flows (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($37,586) | ($29,267) | | Net cash provided by investing activities | $13,530 | $36,163 | | Net cash provided by (used in) financing activities | ($525) | $258 | | **Net (decrease) increase in cash, cash equivalents and restricted cash** | **($24,581)** | **$7,154** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the company's business, accounting policies, recurring losses, and significant financial activities including the Amgen collaboration and a new SVB loan agreement - The company has incurred recurring losses, including a net loss of **$34.1 million** for the three months ended March 31, 2025, and had an accumulated deficit of **$409.2 million**. Management asserts that cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months[37](index=37&type=chunk) - Under the Amgen Collaboration Agreement, the company received a **$30 million** upfront payment and is eligible for over **$500 million** in milestones. In Q1 2025, **$2.2 million** was recognized as revenue from this agreement[52](index=52&type=chunk)[53](index=53&type=chunk)[58](index=58&type=chunk) - In December 2024, the company entered into a new Loan and Security Agreement with Silicon Valley Bank (SVB) for up to **$52.5 million**, with an initial tranche of **$32.5 million** funded. This replaced the previous K2HV loan agreement[65](index=65&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=18&type=section&id=Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's TCR-T therapy development, significant operating losses, and liquidity, projecting existing cash to fund operations into Q1 2027 [Overview](index=18&type=section&id=Overview) TScan is a clinical-stage biotechnology company developing TCR-T therapies for cancer, with lead candidates in Phase 1 trials and a history of significant operating losses - The company is advancing lead product candidates **TSC-100** and **TSC-101** in a Phase 1 trial for heme malignancies (AML, MDS, ALL) in patients undergoing allogeneic HCT[80](index=80&type=chunk) - For solid tumors, the company is developing a multiplex TCR-T therapy (T-Plex) and has seven IND applications cleared by the FDA, with a Phase 1 trial (PLEXI-T™) underway[81](index=81&type=chunk) - The company has incurred significant operating losses since inception, with a net loss of **$34.1 million** for Q1 2025 and an accumulated deficit of **$409.2 million** as of March 31, 2025[84](index=84&type=chunk) [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Collaboration revenue increased, but higher R&D and G&A expenses led to a wider loss from operations of $36.3 million for Q1 2025 compared to Q1 2024 Comparison of Results of Operations (in thousands) | | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | Change | | :--- | :--- | :--- | :--- | | Collaboration and license revenue | $2,171 | $566 | $1,605 | | Research and development | $29,788 | $24,857 | $4,931 | | General and administrative | $8,633 | $7,082 | $1,551 | | **Loss from operations** | **($36,250)** | **($31,373)** | **($4,877)** | - The **$4.9 million** increase in R&D expenses was primarily driven by a **$2.2 million** increase in laboratory supplies and studies related to start-up activities with a global CDMO, and a **$1.6 million** increase in facility-related expenses[91](index=91&type=chunk) - The **$1.6 million** increase in G&A expenses was mainly due to a **$0.4 million** increase in personnel costs from additional headcount and a **$0.3 million** increase in legal and professional fees[92](index=92&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, the company held $251.7 million in cash and equivalents, projected to fund operations into Q1 2027, with recent funding from equity offerings and a new debt facility - The company believes its existing cash, cash equivalents, and marketable securities of **$251.7 million** (as of March 31, 2025) will fund its operating plan into the **first quarter of 2027**[88](index=88&type=chunk)[99](index=99&type=chunk)[100](index=100&type=chunk) - Recent funding includes net proceeds of **$134.7 million** from a June 2023 public offering, **$161.4 million** from an April 2024 offering, and **$30.0 million** from a December 2024 registered direct offering[95](index=95&type=chunk)[96](index=96&type=chunk)[98](index=98&type=chunk) - The company secured a new debt facility with SVB in December 2024 for up to **$52.5 million**, drawing an initial **$32.5 million** and terminating its prior K2HV loan agreement[97](index=97&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a "smaller reporting company," TScan is exempt from providing quantitative and qualitative disclosures about market risk - As a "smaller reporting company," TScan is not required to provide quantitative and qualitative disclosures about market risk[120](index=120&type=chunk) [Item 4. Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of March 31, 2025, the Principal Executive Officer and Principal Financial Officer concluded that the company's disclosure controls and procedures were effective[121](index=121&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended March 31, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[122](index=122&type=chunk) [PART II. OTHER INFORMATION](index=26&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, though future involvement in ordinary course legal matters is possible - The company is not currently a party to any material legal proceedings[124](index=124&type=chunk) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A.%20Risk%20Factors) This section details numerous risks, including financial losses, dependence on novel TCR-T therapy, clinical development challenges, manufacturing complexities, regulatory uncertainty, intellectual property issues, and reliance on third parties [Risks Related to Our Business and Industry](index=27&type=section&id=Risks%20Related%20to%20Our%20Business%20and%20Industry) This subsection outlines fundamental business risks, including a history of significant losses, dependence on the TCR-T platform, limited operating history, and the need for substantial additional funding - The company has a history of significant losses, reporting a net loss of **$34.1 million** for Q1 2025, and expects to incur substantial losses for the foreseeable future[129](index=129&type=chunk) - The business is highly dependent on the success of its proprietary platform to discover and develop TCR-T therapy product candidates, which is a novel approach with significant challenges[131](index=131&type=chunk)[162](index=162&type=chunk) - Substantial additional funding is required to complete development and commercialization. Existing cash is projected to fund operations into Q1 2027, but the company will need to raise more capital, which may not be available on favorable terms[140](index=140&type=chunk)[141](index=141&type=chunk) [Risks Related to the Development of Our Product Candidates](index=33&type=section&id=Risks%20Related%20to%20the%20Development%20of%20Our%20Product%20Candidates) This subsection details risks in product candidate development, including the novelty of TCR-T therapy, potential for undesirable side effects, and the uncertainty of preclinical results predicting clinical success - The company's novel approach to cancer treatment with TCR-T therapy creates significant challenges, including educating medical personnel, managing potential side effects (GvHD, neurotoxicity), and scaling manufacturing[162](index=162&type=chunk)[163](index=163&type=chunk) - Product candidates are in early development, and there is a high risk of failure. Preclinical and early clinical results may not be predictive of later-stage trial success[165](index=165&type=chunk)[174](index=174&type=chunk) - Product candidates may cause undesirable side effects, such as GvHD, autoimmunity, or off-tumor toxicity, which could halt clinical development, prevent regulatory approval, or limit commercial potential[196](index=196&type=chunk)[197](index=197&type=chunk)[198](index=198&type=chunk) [Risks Related to Manufacturing](index=47&type=section&id=Risks%20Related%20to%20Manufacturing) This subsection details manufacturing risks, including the complexity of TCR-T therapy production, reliance on third parties, and challenges in validating processes for diverse patient materials - The manufacturing process for TCR-T therapies is complex, costly, and highly regulated, with risks of product loss or failure due to logistical issues, contamination, or operator error[249](index=249&type=chunk)[251](index=251&type=chunk) - The company has limited experience managing a manufacturing facility and relies on third-party suppliers for critical components, creating risks related to quality control, supply continuity, and scaling up production[250](index=250&type=chunk)[255](index=255&type=chunk) - Difficulties may arise in validating the manufacturing process due to the heterogeneity of patient starting materials, which could impact the ability to produce consistent products for clinical or commercial use[258](index=258&type=chunk)[259](index=259&type=chunk) [Risks Related to Government Regulation](index=48&type=section&id=Risks%20Related%20to%20Government%20Regulation) This subsection covers extensive regulatory risks, including lengthy approval processes, uncertain pricing and reimbursement, and compliance with complex healthcare and data privacy laws - The regulatory approval process for novel product candidates is lengthy, time-consuming, and uncertain, and the company may experience significant delays or may not obtain approval at all[260](index=260&type=chunk)[265](index=265&type=chunk) - Even if approved, the company's products face uncertain and potentially unfavorable pricing, coverage, and reimbursement from government and private payers, which could limit commercial success[291](index=291&type=chunk)[293](index=293&type=chunk) - The company is subject to complex federal, state, and foreign laws regarding healthcare fraud and abuse, as well as data privacy (e.g., GDPR, CCPA), with non-compliance carrying risks of significant fines and penalties[311](index=311&type=chunk)[318](index=318&type=chunk)[321](index=321&type=chunk) [Risks Related to Our Intellectual Property](index=60&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) This subsection details intellectual property risks, including challenges in obtaining and maintaining patent protection, potential infringement claims, and compliance with in-licensed IP agreements - The company's success depends on obtaining and maintaining patent protection, but there is no guarantee that its pending applications will issue as patents with a scope sufficient to protect its product candidates[331](index=331&type=chunk)[334](index=334&type=chunk)[335](index=335&type=chunk) - The company may face costly litigation from third-party claims of IP infringement, which could result in substantial damages or block the commercialization of its products[374](index=374&type=chunk)[375](index=375&type=chunk) - The company relies on licenses from third parties (e.g., BWH) and could lose significant rights if it fails to comply with its obligations under these agreements[346](index=346&type=chunk) [Risks Related to Our Reliance on Third Parties](index=73&type=section&id=Risks%20Related%20to%20Our%20Reliance%20on%20Third%20Parties) This subsection outlines risks from reliance on third parties for clinical trials and manufacturing, including potential delays, quality issues, and challenges in securing future strategic collaborations - The company depends on third parties like CROs and clinical investigators to conduct trials, and their failure to perform their duties properly could delay or compromise clinical development[403](index=403&type=chunk)[404](index=404&type=chunk) - Future strategic collaborations are important for development and commercialization, but the company faces significant competition in seeking partners and may not realize the benefits of such arrangements[406](index=406&type=chunk)[407](index=407&type=chunk) - Reliance on third-party manufacturers for clinical supply exposes the company to risks of production delays, quality control failures, and inability to meet demand, which could halt clinical trials[414](index=414&type=chunk)[415](index=415&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=86&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred, and the planned use of $89.6 million net proceeds from the July 2021 IPO remains materially unchanged - There has been no material change in the planned use of proceeds from the company's July 2021 IPO, which generated net proceeds of **$89.6 million**[472](index=472&type=chunk) [Item 5. Other Information](index=86&type=section&id=Item%205.%20Other%20Information) No director or officer adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during Q1 2025 - No director or officer adopted, modified, or terminated a Rule 10b5-1 trading plan or other trading arrangement during the first quarter of 2025[473](index=473&type=chunk)

Financial Performance - Revenue for Q1 2025 was $2.2 million, a significant increase from $0.6 million in Q1 2024, primarily due to research activities under a collaboration agreement with Amgen[7]. - R&D expenses for Q1 2025 were $29.8 million, up from $24.9 million in Q1 2024, driven by increased laboratory supplies and personnel expenses[8]. - G&A expenses for Q1 2025 were $8.6 million, compared to $7.1 million in Q1 2024, mainly due to higher personnel costs[9]. - Net loss for Q1 2025 was $34.1 million, compared to a net loss of $30.1 million in Q1 2024, including net interest income of $2.1 million[10]. - Cash, cash equivalents, and marketable securities as of March 31, 2025, were $251.7 million, expected to fund operations into Q1 2027[12]. - As of March 31, 2025, the company had 129,678,572 shares outstanding, including pre-funded warrants[13]. Research and Development - The company plans to file an IND application for TSC-102-A0301 in the second half of 2025[11]. - TScan is on track to initiate a registrational trial for TSC-101 in the latter half of 2025[11]. - The first patient for multiplex TCR-T therapy is expected to be dosed in the first half of 2025[11]. - The company continues to develop the ImmunoBank for diverse TCR-T therapy candidates targeting various cancer-associated antigens[6].

Core Insights - TScan Therapeutics is advancing its T cell receptor (TCR)-engineered T cell therapies for cancer treatment, with significant milestones expected by the end of 2025 [1][2][4] Corporate Updates - The company appointed Stephen Camiolo as Senior Vice President, Market Access, bringing over 25 years of experience in the pharmaceutical and biotechnology industries [6] - TScan is on track to file an IND application for TSC-102-A0301 targeting HLA-A*03:01 in the second half of 2025 [1][7] - The company continues to develop its ImmunoBank, a collection of TCR-T therapy candidates targeting various cancer-associated antigens [5][13] Clinical Trials - TScan is enrolling patients in the PLEXI-T solid tumor trial and anticipates dosing the first patient with multiplex therapy soon, with safety and efficacy data expected later this year [2][15] - The ALLOHA Phase 1 trial is ongoing, focusing on TSC-101 for treating acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) [4][7] Financial Performance - Revenue for Q1 2025 was $2.2 million, a significant increase from $0.6 million in Q1 2024, primarily due to research activities under a collaboration agreement with Amgen [8] - R&D expenses rose to $29.8 million in Q1 2025 from $24.9 million in Q1 2024, driven by increased laboratory supplies and personnel costs [9] - G&A expenses increased to $8.6 million in Q1 2025 from $7.1 million in Q1 2024, mainly due to higher personnel expenses [10] - The net loss for Q1 2025 was $34.1 million, compared to $30.1 million in Q1 2024, with cash and cash equivalents totaling $251.7 million as of March 31, 2025, sufficient to fund operations into Q1 2027 [11][12]

Core Insights - TScan Therapeutics, Inc. announced the acceptance of an abstract for a poster presentation at the ASGCT 28th Annual Meeting, highlighting its focus on TCR-engineered T cell therapies for cancer treatment [1][2]. Company Overview - TScan is a clinical-stage biotechnology company specializing in T cell receptor (TCR)-engineered T cell (TCR-T) therapies aimed at treating cancer patients [3]. - The company's lead TCR-T therapy candidates are designed to prevent relapse in patients with hematologic malignancies following allogeneic hematopoietic cell transplantation, specifically through the ALLOHA™ Phase 1 heme trial [3]. - TScan is expanding its ImmunoBank, a repository of therapeutic TCRs that recognize diverse targets across multiple HLA types, to offer customized multiplex TCR-T therapies for various cancers, as seen in the PLEXI-T™ Phase 1 solid tumor trial [3]. - The company is currently enrolling patients in both clinical programs [3]. Presentation Details - The poster presentation titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation" will take place on May 13 from 6:00 - 7:30 p.m. Central Time [2]. - The presentation will be held in the Poster Hall, Hall I2, and materials will be available on the company's website post-presentation [2].

Core Insights - TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on T cell receptor (TCR)-engineered T cell therapies for cancer treatment [3] Group 1: Company Participation - The company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 9:30 a.m. Eastern Time [1] Group 2: Webcast Information - A webcast of the fireside chat will be available on the company's website, with an archived replay accessible for 90 days post-event [2] Group 3: Company Overview - TScan's lead TCR-T therapy candidates are aimed at treating hematologic malignancies to prevent relapse after allogeneic hematopoietic cell transplantation [3] - The company is expanding its ImmunoBank, a repository of therapeutic TCRs for customized multiplex TCR-T therapies targeting various cancers [3] - TScan is currently enrolling patients in both its clinical programs, including the ALLOHA™ Phase 1 heme trial and the PLEXI-T™ Phase 1 solid tumor trial [3]